TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05919264: FOG-001 in Locally Advanced or Metastatic Solid Tumors

Sponsor: Parabilis Medicines, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 619 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$11,191,950

Rescue Site Savings

+$7,382,760

Unlock Full NCT05919264 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05919264 Rescue Dossier →